Russell Elliott Net Worth & Insider Trades
Russell Elliott - VP Drug Development, Foamix Pharmaceuticals Ltd
What is Russell Elliott's Net Worth?
The current estimated net worth of Foamix Pharmaceuticals Ltd's VP Drug Development, Russell Elliott, is estimated to be about $36.8K . Russell Elliott owns about 12,442 units of Foamix Pharmaceuticals Ltd common stock. In the last 9 months at Foamix Pharmaceuticals Ltd, Russell Elliott has sold an estimated value of $10.61K worth.
What is Russell Elliott's Past Insider Trading?
Russell Elliott's largest sale order was 817 units , worth over $5.02K on March 6, 2018. In total, Russell Elliott has made about 6 transactions over 9 months of their time at Foamix Pharmaceuticals Ltd. Russell Elliott usually trades in April, March, October, July, February and January, with the busiest year in 2018. The most recent transaction was a sale order of 142 units , worth over $825.02 on October 2, 2018.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Russell Elliott
Date Range: All Time
Ticker
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
---|---|---|---|---|---|---|---|
No matching records found |
InsideArbitrage
What is Russell Elliott's' Mailing Address?
- Mailing address is C/o Foamix Pharmaceuticals Ltd. 2 Holzman Street, Weizmann Science Park Rehovot L3 76704 Israel
What are Foamix Pharmaceuticals Ltd's Past Insider Trades?
Foamix Pharmaceuticals Ltd's most recent insider trade came on September 11, 2019 by Ilan Hadar who sold 43,812 units worth $153.37K . In the last year, insiders at Foamix Pharmaceuticals Ltd have sold an estimated value of $719.78K and bought an estimated value of $707.22K worth of shares. Insider trading is most common in March, with the busiest year in 2018. The most active traders at the company are David Domzalski, CEO, Iain Stuart, Chief Scientific Officer, and Mutya Harsch, CLO and General Counsel .
Foamix Pharmaceuticals Ltd. Insider Trades
Date Range: All Time
Insider Names
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
---|---|---|---|---|---|---|---|
No matching records found |